Table 3.
Sarcopenia prevalence during neoadjuvant chemotherapy.
| Group | After chemotherapy | |||
|---|---|---|---|---|
| No sarcopenia | Sarcopenia | Total | ||
| Before chemotherapy | No sarcopenia | 208 (92.86%) | 29 (31.18%) | 237 (74.76%) |
| Sarcopenia | 16 (7.14%) | 64 (68.62%) | 80 (25.24%) | |
| Total | 224 (100%) | 93 (100%) | 317 (100%) | |
Pearson χ2(1) = 132.48, p = 0.000.